(Q50117758)

25 February 2018

title

Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. (English)

1 reference

25 February 2018

1 reference

1 reference

1

1 reference

25 February 2018

Elizabeth Miller

8

object named as

Miller E

1 reference

25 February 2018

author name string

Gay NJ

2

1 reference

25 February 2018

Hesketh LM

3

1 reference

25 February 2018

Vyse A

4

1 reference

25 February 2018

Morgan-Capner P

5

1 reference

25 February 2018

Brown DW

6

1 reference

25 February 2018

Litton P

7

1 reference

25 February 2018

language of work or name

English

0 references

publication date

1 January 2002

1 reference

25 February 2018

published in

Vaccine

1 reference

25 February 2018

volume

20

1 reference

25 February 2018

issue

7-8

1 reference

25 February 2018

page(s)

1134-1140

1 reference

25 February 2018

Mumps epidemic in Portugal despite high vaccine coverage - preliminary report.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Outbreak of measles in a teenage school population: the need to immunize susceptible adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Investigation of a measles outbreak in a fully vaccinated school population including serum studies before and after revaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Mumps outbreak in a highly vaccinated population

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Mumps outbreak in a highly vaccinated school population. Evidence for large-scale vaccination failure

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Measles antibody: reevaluation of protective titers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Immunoglobulin M antibody response to measles virus following primary and secondary vaccination and natural virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Immunogenicity and reactogenicity of acellular diphtheria/tetanus/pertussis vaccines given as a pre-school booster: effect of simultaneous administration of MMR.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Ten years of serological surveillance in England and Wales: methods, results, implications and action.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

The European Sero-Epidemiology Network: standardizing the enzyme immunoassay results for measles, mumps and rubella.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Detection of measles, mumps, and rubella antibodies in saliva using antibody capture radioimmunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Correlations between measles, mumps, and rubella serum antibody levels in Olmsted County school children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Twin studies of immunogenicity--determining the genetic contribution to vaccine failure

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Persistent rubella‐specific IgM reactivity in the absence of recent primary rubella and rubella reinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Protection after two doses of measles vaccine is independent of interval between doses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Increased protections during a measles outbreak of children previously vaccinated with a second dose of measles-mumps-rubella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900435-2

7 January 2021

10.1016/S0264-410X(01)00435-2

Identifiers

DOI

1 reference

25 February 2018

PubMed ID

11803074

1 reference

25 February 2018